Search the Newsreel

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic …

ETFs Investing in Mesoblast Limited Sponsored ADR Stocks

This article lists various ETFs that include Mesoblast Limited Sponsored ADR (A4004R) stocks in their holdings. The ETFs are sorted by market value and provide details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. …

Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:MESO) 2026-08-12

Genesis Minerals And 2 Other ASX Stocks That Might Be Trading Below Estimated Value

This article identifies Genesis Minerals (ASX:GMD), Lycopodium (ASX:LYL), and Mesoblast (ASX:MSB) as potentially undervalued ASX stocks based on their estimated future cash flows. Genesis Minerals is involved in gold mining, Lycopodium provides engineering services, and Mesoblast develops regenerative medicine products. Each company is trading …

Mesoblast Ltd (MESO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mesoblast Ltd (MESO) has an earnings forecast score of 8.00, ranking 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $35.00 for MESO, with most analysts recommending a "Buy" trend. The stock closed at $15.940, indicating a …

CCORF Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $2.5

CCORF has reiterated its Buy rating for MESOBLAST LTD (MEOBF.US) and increased its price target to $2.5. This indicates a positive outlook on the company's future performance and stock value.

Jameson Resources Sharpens Leadership as Crown Mountain Steelmaking Coal Project Advances

Why DroneShield (ASX:DRO), Sigma Healthcare (ASX:SIG) And Mesoblast (ASX:MSB) Are Drawing Attention

The article highlights DroneShield (ASX:DRO), Sigma Healthcare (ASX:SIG), and Mesoblast (ASX:MSB) as companies attracting investor attention. DroneShield is noted for its counter-drone technology, Sigma Healthcare for pharmaceutical distribution, and Mesoblast for biotechnology and regenerative medicine. These companies are generating interest due to their financial …

Mesoblast Ltd (MESO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mesoblast Ltd (MESO), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock currently has a price momentum score of 4.88 and is trading between a resistance level of 18.05 and a …

Ryoncil sales hit US$115M as Mesoblast (Nasdaq: MESO) advances late-stage trials

Mesoblast Limited reported preliminary Ryoncil® net revenue of US$36 million for Q4 and US$115 million for the first full year after FDA approval, maintaining US$103 million in cash as of June 30, 2026. The company is actively advancing its pipeline with trials for Ryoncil …

Mesoblast Q4 Results: Ryoncil revenue hits US$36M, cash at US$103M

Mesoblast Limited announced strong Q4 results, with Ryoncil generating US$36 million in revenue, contributing to a full-year total of US$115 million. The company's cash position stands at US$103 million after drawing down US$50 million to clear debt. Mesoblast is focused on expanding Ryoncil's label …

Mesoblast Back Pain Trial Reaches at Least 300 Patients

Mesoblast reported preliminary Ryoncil® net revenues of US$36 million for Q4 2026 and US$115 million for the full year post-FDA approval, alongside operational achievements. These include enrolling at least 300 patients in a pivotal Phase 3 trial for chronic low back pain and receiving …

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June 30, 2026 (Appendix 4C) NEW YORK, July 29, …

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Jefferies Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $2.09

Jefferies has reiterated its Buy rating on MESOBLAST LTD (MEOBF.US) and increased its price target to $2.09. This updated target suggests continued confidence in the company's prospects.

Mesoblast Ltd (MESO) Earnings Date & Reports & Earnings News

Mesoblast (ASX:MSB) Completes Enrolment in Its Pivotal Back-Pain Trial—Is a Multibillion-Dollar Market Moving Within Reach?

Mesoblast (ASX:MSB) has completed enrolment for its pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L, an experimental therapy for chronic low back pain associated with degenerative disc disease. This milestone brings the company closer to potentially tapping into a multibillion-dollar market, with top-line results expected …

Mesoblast Ltd (MESO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mesoblast Ltd (MESO), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides a quarterly breakdown of institutional shareholding trends over the past few years, along with …

Mesoblast Ltd (MESO) Institutional Confidence

This article focuses on the institutional confidence score for Mesoblast Ltd (MESO), which currently stands at 3.00, unchanged from the previous score. It details major institutional shareholders and their recent activity, including increases in holdings by BlackRock Institutional Trust Company and Susquehanna International Group, …

Mesoblast Ltd (MESO) Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Mesoblast Ltd (MESO), allowing users to evaluate the company's financial soundness. It breaks down operating, investing, and financing cash flows, including detailed historical data. The document also includes an FAQ section explaining key …

Mesoblast Ltd (MESO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mesoblast Ltd's (MESO) dividend and stock split history. It notes that no dividends have been distributed by the company in the past five years. The article also details several stock split events, all identified as a "Merger 2→1" …

MESO|Mesoblast Ltd|Price:15.310|Chg%:-0.770

Mesoblast Ltd (MESO) is an Australian company developing allogeneic cellular medicines for inflammatory conditions. Despite its strong revenue growth averaged at 129.28% over the past three years and high profit growth, the stock experienced a 4.79% drop, trading at $15.31. Analysts currently rate MESO …

Mesoblast Ltd (MESO) Valuation: PE, PB & Fair Value Analysis

This article analyzes Mesoblast Ltd's (MESO) valuation, noting a current score of 9.84, placing it 10th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is currently -18.10. The article also mentions that relevant data for P/B, P/S, and …

Mesoblast (ASX:MSB) Slides to $2.22 After Remaining Under Pressure Over the Year

Mesoblast (ASX:MSB) shares fell 4.31% to AUD 2.22 on July 24, 2026, marking a 13.95% decline over the past year. The biotechnology company, valued at AUD 3.01 billion, focuses on regenerative medicine. Investors are advised to look beyond daily stock fluctuations and consider factors …

State Street Global Advisors Ceases Substantial Holding in Mesoblast Limited

State Street Global Advisors and its subsidiary entities are no longer substantial holders in Mesoblast Limited (ASX: MSB) as of July 22, 2026. This change follows multiple share movements and stock lending transactions between March and July 2026, which reduced State Street's interest below …

Mesoblast (ASX:MSB) Dips Today — Should Investors Be Watching This Cell Therapy Biotech?

Mesoblast (ASX:MSB) shares fell 0.86% to $2.32 on July 23, 2026, contributing to a 2.93% decline over the past year. This dip occurred alongside a broader 1.43% decline in the S&P/ASX 200 Health Care Index. Mesoblast, with a market capitalization of AUD 3.01 billion, …

Mesoblast Says JPMorgan Chase Cease to Be Substantial Holder

Mesoblast has announced that JPMorgan Chase is no longer a substantial holder in the company. This disclosure indicates a change in the ownership structure of Mesoblast, as JPMorgan Chase has reduced its stake below the reporting threshold.

Mesoblast (ASX: MSB) Slides 5.8% on Strong Volume — Why the Biotechnology Stock Is Back in Focus

Mesoblast (NASDAQ: MESO) CEO invests A$2,733,734 to exercise options

Mesoblast CEO Dr. Silviu Itescu exercised 1,885,334 options on ordinary shares for A$2,733,734, increasing his total shareholding to over 80.8 million shares. This investment reflects his strong confidence in the company's growth, which is a global leader in allogeneic cellular medicines including FDA-approved Ryoncil. …

Mesoblast Limited Issues 1.9 Million Ordinary Shares Through Employee Option Exercise Programme

Mesoblast Limited (MSB) has applied for the quotation of 1,885,334 ordinary fully paid shares issued on July 16, 2026, under its employee share option plan. This issuance follows the exercise of vested options by an employee share plan trustee for nil cash consideration, aligning …

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Mesoblast Limited (MESO) is identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of 'A'. The article highlights MESO's recent price performance, outperforming its industry and the S&P 500, and positive earnings estimate revisions as …

Bell Potter Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $3.08

Bell Potter has reiterated its "Buy" rating for MESOBLAST LTD (MEOBF.US) and increased its target price to $3.08. The analyst firm's continued positive outlook suggests confidence in the company's future performance and potential for stock appreciation.

Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally